Haleon plc filings document foreign private issuer disclosures for a global consumer health company whose American depositary shares trade under HLN. Form 6-K reports cover current information such as trading statements, ordinary-share repurchases for cancellation, total voting rights and capital, and annual general meeting poll results.
The filing record also includes debt-market disclosures, including listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V. guaranteed by Haleon. Governance and capital-structure disclosures address directors' remuneration, board elections, dividend approvals, special resolutions, ordinary shares, treasury shares, voting rights and shareholder notification thresholds.
Haleon plc reported its share count and voting rights as of 31 December 2025. The company had a total of 8,952,353,648 ordinary shares of £0.01 each in issue, of which 45,745,646 were held as treasury shares without voting rights.
After excluding treasury shares, the number of ordinary shares with voting rights was 8,906,608,002. Shareholders and others with disclosure obligations are asked to use this figure as the denominator when calculating whether they need to notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc announced changes to its board and committees. Alan Stewart will become Senior Independent Director when Vindi Banga is appointed Chair with effect from 1 January 2026. Stewart joined the board in September 2024 as a Non-Executive Director and Chair of the Audit & Risk Committee, and he will retain that position while also remaining on the Remuneration, Nominations & Governance and Environmental & Social Sustainability Committees.
In line with the UK Corporate Governance Code 2024, Vindi Banga will step down from the Audit & Risk Committee and the Remuneration Committee on 31 December 2025 and will become Chair of the Nominations & Governance Committee from 1 January 2026. Haleon confirmed that Banga’s remuneration as Chair will be £757,103 per annum, with further details to be included in the Company’s 2025 Annual Report & Accounts.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. On 9 December 2025, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 35 partnership shares in Haleon at a price of £3.57201 per ordinary share and received 35 matching shares at no cost. These ordinary shares have a nominal value of £0.01 each and are listed on the London Stock Exchange. The disclosure is made in line with UK Market Abuse Regulation requirements for transactions by persons discharging managerial responsibilities.
Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reported PDMR share transactions under its Share Reward Plan. On 11 November 2025, Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 33 ordinary shares at £3.718992 and received 33 matching shares at £Nil on the London Stock Exchange.
These notifications were made in accordance with the UK Market Abuse Regulation and reflect routine participation in the company’s employee share plan.
Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Banga has served as Senior Independent Director since Haleon’s 2022 listing and brings extensive global consumer leadership experience, including 33 years at Unilever and roles at UK Government Investments and GSK. The Board’s decision was unanimous. Remuneration details and a successor for Senior Independent Director will be announced before his appointment takes effect.
Haleon plc reported its total voting rights and capital. As at 31 October 2025, the Company had 8,952,353,648 ordinary shares issued, including 45,930,962 held as treasury shares. After excluding treasury shares, the number of ordinary shares with voting rights is 8,906,422,686.
This voting-rights figure is the denominator shareholders and other obliged parties should use when assessing notification thresholds under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.
The Company will host a short presentation and Q&A at 9:00am GMT (10:00am CET) on 30 October 2025, led by Chief Financial Officer Dawn Allen, with access via www.haleon.com/investors.
Dial-in details include UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228. An archived webcast will be available later the same day.
Haleon plc filed a Form 6-K reporting notifications of transactions by persons discharging managerial responsibilities on 10 October 2025. The disclosure shows an allotment of £3.4352 per share for 37 matching shares as the reported trade. The notice is a regulatory disclosure under the UK Market Abuse Regulation and provides routine transparency about insider dealings. The report lists the company's well-known consumer health brands and is signed by the Company Secretary on 10 October 2025.
Haleon plc filed a Form 6-K notifying investors that Tracy Clarke, a current Non-Executive Director of Haleon, will be appointed as a Non-Executive Director of Inchcape plc effective 31 December 2025. The disclosure was made to satisfy paragraph 6.4.9R(2) of the UK Listing Rules and is presented as a director declaration in the exhibit. The report is dated 02 October 2025 and signed by Amanda Mellor, Company Secretary. The filing reiterates Haleon’s consumer health focus and lists major product categories and brands for context.